Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 231

UL takes a risk on KenSci in $22m round

UL Ventures' parent company will offer assistance in growth and compliance to the healthcare risk assessment platform developer, which has just raised series B funding.

Feb 12, 2019

KenSci foretells $22m series B

The UW-founded healthcare forecasting software developer has collected $30.5m in all from backers including OUP and a unit of compliance firm UL.

Feb 12, 2019

Cisco hits Gong in $40m series B

Existing investor Cisco chipped in for a series B round that boosted sales data platform Gong.io's overall funding to $68m.

Feb 11, 2019

Amazon drives $530m in funding for Aurora

Amazon and Shell have invested in driverless car software and hardware developer Aurora Innovation at a valuation above $2.5bn, in a round led by Sequoia Capital.

Feb 8, 2019

Spin Memory banks Abies for series B

NYU and Allied Minds-founded Ram technology developer Spin Memory has unveiled deep tech-focused VC firm Abies Ventures as an investor in a $52m series B first announced late last year.

Feb 8, 2019

Calm meditates on $88m series B

The meditation app developer has quadrupled its valuation to $1bn in just eight months, in an $88m series B round featuring CAA.

Feb 7, 2019

Aetion advances series B past $63m

Sanofi, UCB, Horizon Health Services and McKesson Ventures added $27m to a series B round for the medical data software provider that already included Amgen Ventures.

Feb 7, 2019

Healthy.io takes home $18m

Samsung Next has taken part in a series B round that will fund the roll out of Healthy.io's home urinalysis analyser system in the UK and expansion in the US.

Feb 7, 2019

Vinli makes tracks with Eon-backed series B

The automotive data platform developer, which counts Samsung, Cox Enterprises and Continental as shareholders, has secured $13.5m in its series B round.

Feb 7, 2019

Bolt hits series B with $54m

Nan Fung Life Sciences and Novo have taken part in a series B round for Stanford's immuno-oncology drug developer Bolt Biotherapeutics.

Feb 6, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here